Medicines and Healthcare products Regulatory Agency
1: Authorisation Number | UK MIA(IMP) 48152 |
---|---|
2: Name of authorisation holder | CELL AND GENE THERAPY CATAPULT |
3: Address(es) of manufacturing site(s) |
CELL AND GENE THERAPY CATAPULT MANUFACTURING AND INNOVATION CENTRE, 4 WARNER DRIVE, SPRINGWOOD INDUSTRIAL ESTATE, BRAINTREE, CM7 2YW, UNITED KINGDOM |
4: Legally registered address of authorisation holder | CELL AND GENE THERAPY CATAPULT, 12TH FLOOR TOWER WING, GUY'S HOSPITAL, GREAT MAZE POND, LONDON, SE1 9RT, UNITED KINGDOM |
5: Scope of authorisation and dosage forms | ANNEX 1 and/ or ANNEX 2 |
6: Legal Basis of authorisation | |
7: Name of responsible officer of the competent authority of the member state granting the manufacturing authorisation | Confidential |
8: Authorisation Date | 02/02/2024 |
9: Annexes attached | Annex 1 and/or Annex 2 |
SCOPE OF AUTHORISATION
Annex 2
Name and address of the site:
CELL AND GENE THERAPY CATAPULT MANUFACTURING AND INNOVATION CENTRE, 4 WARNER DRIVE, SPRINGWOOD INDUSTRIAL ESTATE, BRAINTREE, CM7 2YW, UNITED KINGDOM
Human Investigational Medicinal Products
Authorised Operations |
MANUFACTURING OPERATIONS (according to part 1) |
Part 1 - MANUFACTURING OPERATIONS |
[ 1.1 ] Sterile Investigational Medicinal Products |
[ 1.1.1 ] Aseptically prepared (processing operations for the following dosage forms) |
[ 1.1.1.1 ] Large volume liquids Special Requirements Live Cells Advanced Therapy Medicinal Products |
[ 1.1.1.4 ] Small volume liquids Special Requirements Live Cells Advanced Therapy Medicinal Products |
[ 1.1.1.6 ] Other aseptically prepared products Cell and viral vector based Advanced Therapeutic Medicinal Products Special Requirements Live Cells Advanced Therapy Medicinal Products |
[ 1.1.3 ] Batch certification |
[ 1.3 ] Biological investigational medicinal products |
[ 1.3.1 ] Biological medicinal products |
[ 1.3.1.3 ] Cell therapy products Special Requirements Live Cells Advanced Therapy Medicinal Products |
[ 1.3.1.4 ] Gene therapy products Special Requirements Live Cells Advanced Therapy Medicinal Products |
[ 1.3.1.5 ] Biotechnology products Special Requirements Live Cells Advanced Therapy Medicinal Products |
[ 1.3.1.6 ] Human or animal extracted products Special Requirements Live Cells Advanced Therapy Medicinal Products |
[ 1.3.1.8 ] Other biological medicinal products Viral vectors Special Requirements Live Cells Advanced Therapy Medicinal Products |
[ 1.3.2 ] Batch certification |
[ 1.3.2.3 ] Cell therapy products Special Requirements Live Cells Advanced Therapy Medicinal Products |
[ 1.3.2.4 ] Gene therapy products Special Requirements Live Cells Advanced Therapy Medicinal Products |
[ 1.3.2.5 ] Biotechnology products Special Requirements Live Cells Advanced Therapy Medicinal Products |
[ 1.3.2.6 ] Human or animal extracted products Special Requirements Live Cells Advanced Therapy Medicinal Products |
[ 1.3.2.8 ] Other biological medicinal products Viral vectors Special Requirements Live Cells Advanced Therapy Medicinal Products |
[ 1.4 ] Other investigational medicinal products or manufacturing activitiy |
[ 1.4.2 ] Sterilisation of active substances/excipients/finished products: |
[ 1.4.2.1 ] Filtration |
[ 1.5 ] Packaging |
[ 1.5.1 ] Primary packaging |
[ 1.5.1.6 ] Liquids for internal use |
[ 1.5.1.15 ] Other non-sterile medicinal products Cell based Advanced Therapeutic Medicinal Products |
[ 1.5.2 ] Secondary packaging |
[ 1.6 ] Quality control testing |
[ 1.6.1 ] Microbiological: sterility |
[ 1.6.2 ] Microbiological: non-sterility |
[ 1.6.3 ] Chemical/Physical |
[ 1.6.4 ] Biological |